RANBAXY ANNOUNCES SETTLEMENT
OF ACTOS® (PIOGLITAZONE HYDROCHLORIDE) PATENT LITIGATION
Jacksonville, FL – March 15,
2010 -- Ranbaxy Laboratories Limited , along
with its wholly owned subsidiary Ranbaxy Pharmaceuticals
Inc. (collectively, “Ranbaxy”), announced
today that they have reached an agreement with Takeda
Pharmaceutical Company Limited and Takeda Pharmaceuticals
North America resolving outstanding patent litigation
related to Ranbaxy's generic equivalent version of Actos®
(Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg
tablets. Under terms of the agreement, Takeda granted
Ranbaxy a non-exclusive royalty free license to its
U.S. patents covering Actos®. Under the terms of
the agreement, Ranbaxy has certainty in the launch of
its generic equivalent formulation of Actos® on
August 17, 2012, or earlier under certain circumstances.
Actos® had approximately $3.4 billion in brand sales
for the twelve months ending December 31, 2009, according
to IMS Health. Actos® is a once-daily oral prescription
medication that, with diet and exercise, has been shown
to be effective for the treatment of type 2 diabetes.
“This agreement will allow RPI to bring to patients
with diabetes a generic alternative in this important
therapeutic area,” according to Jim Meehan, Vice
President of Sales and Distribution for RPI.
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville,
Florida, is a wholly owned subsidiary of Ranbaxy Laboratories
Limited (RLL), India’s largest pharmaceutical
company. RPI is engaged in the sale and distribution
of generic and branded prescription products in the
U.S. healthcare system.
Ranbaxy Laboratories Limited, headquartered in India,
is an integrated, research based, international pharmaceutical
company producing a wide range of quality, affordable
generic medicines, trusted by healthcare professionals
and patients across geographies. Ranbaxy’s continued
focus on R&D has resulted in several approvals in
developed markets and significant progress in New Drug
Discovery Research. The Company’s foray into Novel
Drug Delivery Systems has led to proprietary "platform
technologies", resulting in a number of products
under development. The Company is serving its customers
in over 125 countries and has an expanding international
portfolio of affiliates, joint ventures and alliances,
ground operations in 46 countries and manufacturing
operations in 7 countries. Ranbaxy is a member of the
Daiichi Sankyo Group. Daiichi Sankyo is a leading global
pharma innovator, headquartered in Tokyo, Japan.
* Actos® is a registered trademark of Takeda
Chemical Industries, Ltd.
|
